Dermatology Drugs Market (By Indication: Acne, Psoriasis, Rosacea, Alopecia, Others; By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies; By Administration Analysis: Topical Administration, Oral Administration, Parenteral Administration) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032

The global dermatology drugs market size accounted for USD 17.24 billion in 2022 and is projected to hit around USD 51.32 billion by 2032, growing at a CAGR of 11.53% during the forecast period 2023 to 2032.

Access our Premium Real Time Data Intelligence Tool, Visit: Precedence Statistics

Dermatology is a field of medication that focuses on identifying, preventing, and treating conditions that affect the skin, including those that affect the hair as well as nails. Drugs used in dermatology are used to control and treat conditions affecting the skin, hair, nails, and genital membranes.

Key Points:

• On the basis of indication, the psoriasis segment has captured a market share of over 35.50% in 2022 and is expected to grow at the highest CAGR of 11.8% from 2023 to 2032. 
• On the basis of the distribution channel, the hospital pharmacy segment commands the greatest proportion.
• In 2022, the parenteral administration market sector held a monopoly
• On the basis of administration analysis, the parenteral administration segments sector held a monopoly.
• The North America region has held the highest revenue share of around 39.50% in 2022.

Growth Factor

The market for dermatological medications is expanding as a result of the rise in patients with dermatitis, fungal, and acne. According to data from the American Association of Dermatologists, acne affects almost 50 million individuals in the US alone. Skin and other associated issues can arise for a variety of causes, including improper body care, excessive perspiration, consuming hot foods, and wearing constricting clothing. As a result, the market is observing a rise in the sales of medications used for treatments. It has been demonstrated that increased public knowledge of skin and hair infections presents a potential opportunity for the industry. The sale of over-the-counter (OTC) medications, which are frequently used to treat hair loss and acne, has increased as a result of increased knowledge. Due to hormonal fluctuations, most young people and teenagers have skin-related problems such as skin irritability, acne, and excessive perspiration. The market is anticipated to continue expanding because of the increase in demand for dermatological medications that are regularly used as anti-inflammatory agents and cleansers topically.  Other considerations include an increase in spending on R&D by industry leaders for the creation and clinical testing of new medications as a result of the rise in demand for innovative, efficient, and affordable medications. The rise in skin cancer cases and other illnesses is contributing to the expansion of the pharmaceutical industry. However, a number of adverse effects and inappropriate application of dermatological medications, together with governmental limitations and guidelines, will prevent the industry from developing to its full potential.

• Increasing health insurance coverage and rising consumer desire for perfect skin are fueling industry expansion.
• The market is being boosted by the growing adoption of skincare goods, including dermatological medications, due to rising disposable income throughout the world.
• The need for dermatological medications is rising as personal care spending and knowledge of skin conditions and nail health rise.
• According to projections, there will be a rise in patients due to the prevalence of skin cancer and the prevalence of skin illnesses worldwide.
• The market is being driven in large part by the rising need for skin problem diagnosis and treatment.

Report Scope of the Dermatology Drugs Market

Key Market Drivers

The prevalence of dermatological disorders is rising

• Globally, there will be a greater need for innovative products as the number of people with vitiligo, dermatitis, and acne increases. For instance, the American Association of Dermatology estimates that around 50 million people experienced acne in 2018. The need for goods that effectively treat infections will thus increase as a result of this. According to Australian studies, acne vulgaris affects more than 4% of people over the long term. As a result, it is predicted that the market would rise during the forecast period due to an increase in the frequency of skin disorders and the demand for efficient medications.

Launch of therapeutically effective drugs 

• The worldwide dermatological pharmaceuticals industry is anticipated to be more affected by the regular release of innovative and customer-focused products. For instance, Sanofi's medication dupixent, which is intended to treat atopic dermatitis in children aged 6 to 11 years, was approved by the U.S. FDA in May 2020. Additionally, Cosmedix announced the arrival of the proper fast-relief acne treatment solution in March 2020. During the projected period, marketing tactics such as website launches, TV and social media advertisements raising campaign awareness, and others will also help the market develop.

Key Market Challenges

Risk of side effects about improper use of products 

• Emerging nations account for a substantial share of the world's population with dermatological infections as a result of poor food, pollution, and unhealthy habits like smoking, drinking, etc. Lack of knowledge about skin issues and a greater percentage of illiteracy in low- and middle-income nations have resulted in reduced uptake of items used to treat dermatological conditions. The negative side effects of the products also prevent the market from expanding. For instance, the US FDA issued a warning on the use of some over-the-counter drugs that might result in potentially fatal allergic reactions. This will probably result in less product acceptance, which will diminish the market value of dermatological medications.

Key Market Opportunities

Increasing elderly population

• The aging process of human skin, which results in a variety of skin diseases, is what is driving the growth of the dermatological medicines industry. The body also starts to encounter a number of other problems as we age, such as delayed wound healing, greater sensitivity to ultraviolet (UV) radiation, increased susceptibility to infections, and diminished subcutaneous fat. The need for dermatological drugs has soared as the risk of several skin disorders has grown.

Increasing personal care spending is driving demand for dermatology drugs

• Healthcare spending has risen over time along with disposable income. The Organization for Economic Co-operation and Development (OECD) announced that the U.S. saw a 2.3% growth in disposable income from 2016 to 2017. Furthermore, according to the OECD, skin illnesses accounted for almost 3% of all medical expenses in Germany in 2016. As a result, individuals are spending a sizeable portion of their money on dermatology and related services as they become more aware of various skin illnesses, which has fueled the expansion of the dermatological pharmaceuticals market.

Segments Insight

Indication Insights

With a revenue share of more than 35.50% in 2022, the psoriasis category led the market and is predicted to grow at the highest CAGR of 11.8% from 2023 to 2032. The immune system incorrectly attacks healthy skin cells, which results in psoriasis. Psoriasis is not a disease that spreads easily. Swollen fingers and toes, foot discomfort, lower back pain, nail alterations, and eye irritation are all symptoms of the illness. Stress, skin injuries, infections, certain medicines, and frequent drinking can all cause psoriasis. Although it affects people of all ages, psoriasis is more common in adults, which increases the need for dermatological drugs globally.

From 2023 to 2032, the alopecia market is anticipated to grow at the second-highest CAGR of 11.20%. Alopecia is a condition where hair follicles are attacked by the body's immune system, leading to hair loss. An autoimmune condition called alopecia causes hair to fall out. Due to hormonal imbalances, hair care products, scalp infections, and potential drug side effects, both men and women get alopecia. Additionally, the most typical reason for hair loss worldwide is inherited. People are cautious about hair loss and seek diagnosis at hospitals. Hair loss contributes to the market growth rate and necessitates long-term continuous treatments.

Distribution Channel Insights

Due to a growth in patient visits and sales of prescription-only medications for the treatment of dermatological skin problems, the hospital pharmacy segment commands the greatest proportion of the worldwide dermatology drug market. This segment is expanding as a result of an increase in patient preference for local pharmacies and the accessibility of inexpensive OTC products. Due to the widespread use of online portals and websites like Amazon and Walmart, the online pharmacy market is anticipated to grow at a profitable CAGR over the course of the projected period.

Administration Analysis Insights

In 2022, the parenteral administration market sector held a monopoly. The introduction of biologics for the treatment of dermatological disorders is responsible for the segment's dominance. Furthermore, it is anticipated that a growth in patient desire for tropical remedies would drive up sales of the items. Due to the US FDA's clearance of oral medicines, the oral category is predicted to have a substantial CAGR throughout the projection period.

Dermatology Drugs Market Share, By Region, 2022 (%)

Regional Insights

The North America region accounted for 39.50% of the revenue share in 2022. Due to the greater prevalence of skin conditions and diseases in the continent, North America accounted for the bulk of the market. According to statistics from statistica.com, in the US, those between the ages of 18 and 29 made the largest proportion of dermatologist visits, at 16.9%, followed by those between 50 and 64 at 15.73%, and those between 30 and 49 at 12.91%. Additionally, the introduction of new medications and the existence of significant industry-important players are fueling market expansion. The primary market growth contributors in the area are the USA, Canada, and Mexico. Because big businesses make significant investments in research and development for the creation of new pharmaceuticals, the European area ranks second on the market. The market is being driven by an increase in the prevalence of skin diseases among individuals and a decrease in the number of visits people are making for treatment. The fourth most prevalent sickness among people is a skin problem or disease, which has led to an increase in medicine demand throughout time. Due to the greater number of young patients, France, Germany, and Italy are the main contributors to the market growth in the area. Due to the relocation of important regional companies and growing awareness, the Middle East and Africa market is also exhibiting growth rates.

Because of the area's increased awareness of skin diseases and access to effective skin treatments, the Asia-Pacific region is anticipated to have the largest market growth. The market expansion has been encouraged by the availability of appropriate healthcare facilities. The annual Asia-Pacific Dermatology conference, which is held in several countries, is the main driver of market expansion in this area. where countries in the Asia-Pacific region congregate to talk about advancement, cooperation, concepts for better patient care, and medication development in the area. The three countries with the largest market shares in the area are China, Japan, and India.

Recent Developments

• In June 2019, DUOBRIITM Lotion was launched in the United States by Bausch Health Companies Inc. and Ortho Dermatologics. DUOBRII, which received approval from the US Food and Drug Administration on April 25, 2019, is the first and only topical lotion to include halobetasol propionate and tazarotene combined in a single formulation.
• In April 2019, the US FDA granted SKYRIZITM, an interleukin-23  inhibitor, approval for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. 

Key Market Players

• LUPIN (India)
• Novartis AG (Switzerland)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Pfizer Inc. (U.S.)
• Sanofi (France)
• Amgen inc. (U.S.)
• Lilly (U.S.)
• AstraZeneca (U.K.)
• AbbVie Inc (U.S.)
• Johnson & Johnson Private Limited (U.S.)
• LEO Pharma A/S (Denmark)
• Merck & Co., Inc (U.S.)
• Bausch Health Companies Inc (Canada)
• Bristol-Myers Squibb Company (U.S.)

Segment Covered in the Report

(Note*: We offer reports based on sub-segments as well. Kindly, let us know if you are interested)

By Indication

• Acne
• Psoriasis
• Rosacea
• Alopecia
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies 

By Administration Analysis

• Topical Administration
• Oral Administration
• Parenteral Administration

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)